At present, according to the National Comprehensive Cancer Network (NCCN) guidelines, the second-generation ALK-tyrosine kinase inhibitors (TKIs), alectinib and brigatinib, and the third-generation ALK-TKI, lorlatinib, are the preferred first-line treatment recommendations for advanced NSCLC patients with ALK gene rearrangements [3]. Here, ALK is linked to non-small cell lung carcinoma.